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Abstract
Incorporation of 5 mol% poly(ethylene glycol)-conjugated lipids (PEG-lipids) has been shown to extend the circulation
longevity of neutral liposomes due to steric repulsion of PEG at the membrane surface. The effects of PEG-lipids on protein
interactions with biologically reactive membranes were examined using phosphatidylserine (PS) containing liposomes as the
model. Incorporating 15 mol% 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE)-PEG 2000 into PS liposomes
resulted in circulation lifetimes comparable to that obtained with neutral liposomes containing 5 mol% DSPE-PEG 2000.
These results suggested that 15 mol% DSPE-PEG 2000 may be effective in protecting PS liposomes from the high affinity,
PS-mediated binding of plasma proteins. This was determined by monitoring the effects of PEG-lipids on calcium-mediated
blood coagulation protein interactions with PS liposomes. Prothrombin binding and procoagulant activity of PS liposomes
could be inhibited s 80% when 15 mol% DSPE-PEG 2000 was used. These results are consistent with PS on membrane
surfaces forming transient nucleation sites for protein binding that may result in lateral exclusion of PEG-lipids incorporated
at 6 10 mol%. These nucleation sites may be inaccessible when PEG-lipids are present at elevated levels where they adopt a
highly compressed brush conformation. This suggests that liposomes with reactive groups and PEG-lipids may be
appropriately designed to impart selectivity to protein interactions with membrane surfaces. ß 2001 Elsevier Science B.V.
All rights reserved.
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1. Introduction
The physical, chemical and biological properties of
membrane surfaces derivatized with poly(ethylene
glycol) (PEG) have been extensively studied over
the past decade. Much of this interest arose from
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attempts to utilize polymers as ‘cloaking’ agents in
order to extend blood residence times of various
macromolecule-based pharmaceutical formulations.
For liposomal delivery systems, poly(ethylene gly-
col)-derivatized phosphatidylethanolamine (PE-
PEG) provided a synthetic alternative to ganglioside
GM1, a naturally occurring glycosylated lipid that
had been shown to signi¢cantly increase the circula-
tion longevity of 100 nm diameter liposomes into
which it had been incorporated [1]. This e¡ect was
correlated with the ability of surface polymers to
reduce plasma protein binding to liposomes, thus
minimizing their recognition and removal from the
blood by the cells of the mononuclear phagocytic
system (MPS) through a process referred to as opso-
nization [2].
It is generally accepted that the characteristics of
reduced protein binding and MPS clearance associ-
ated with PEG containing liposomes are due to the
‘steric stabilization’ properties imparted by the exten-
sion of PEG polymers away from the liposome sur-
face [3,4]. This characteristic arises from the high
degree of water binding by the surface PEG poly-
mers and the ability of the random coil conformation
to provide a ‘mushroom-shaped’ physical barrier to
many proteins and larger biological structures [5,6].
The degree of surface binding inhibition provided by
PEG on the membrane surface depends on the mo-
lecular weight of the PEG polymer, the concentra-
tion of poly(ethylene glycol)-lipid conjugate (PEG-
lipid) in the bilayer and the molecular weight (size)
of the membrane binding ligand. For example, lipo-
some-cell interactions can be reduced with as little as
0.5 mol% PE-PEG 2000 incorporation whereas inhi-
bition of liposome binding for small macromolecules
(i.e. Mr6 20 000) requires between 5 and 7 mol% PE-
PEG 2000 or between 10 and 20 mol% PE-PEG 750
[7,8]. It is in these ranges of incorporation into phos-
pholipid bilayers that the PEG molecules begin to
adopt a more ordered and extended ‘brush’ state. It
may not be surprising, then, that the sterically stabi-
lized liposome composition most typically employed
for intravenous drug delivery contains 5 mol%
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[poly(ethylene glycol) 2000] (DSPE-PEG 2000) in
order to limit liposome interactions with cells and
reduce binding of small molecular weight compo-
nents present in plasma.
The vast majority of studies with PEG containing
membranes have been performed with liposomes
composed of lipids exhibiting no net charge such as
phosphatidylcholines, sphingomyelins and cholester-
ol. Indeed, when more reactive lipids such as the
negatively charged phospholipid phosphatidylserine
(PS) were incorporated into liposomes containing
PE-PEG 2000, these previously sterically stabilized
liposomes became readily recognized by the MPS
and were removed very rapidly from the circulation
[9,10]. Current trends in the development of lipo-
somal delivery vehicles are moving increasingly to-
wards the inclusion of reactive lipid species to assist
in entrapment/retention of agents (e.g. drugs, DNA,
peptides) or to facilitate the transformation of lipo-
somes from being stable in the circulation to being
reactive or unstable once they have reached their
intended target. Consequently, there is a need to bet-
ter characterize the steric stabilization e¡ects of
PEG-lipids in liposomes that display reactive mem-
brane surfaces in order to control their exposure
under conditions where they may be employed.
The negatively charged phospholipid PS has long
been recognized for its involvement in numerous bio-
logical processes including blood coagulation, com-
plement activation and removal of senescent cells
from the blood [11^13]. As described above, lipo-
somes containing PS bind high amounts of plasma
proteins and are removed from the circulation within
minutes after i.v. injection. They accumulate primar-
ily in the liver where Kup¡er cells phagocytose the
opsonized liposomes [14]. In the studies described
here, we have investigated the steric stabilization
properties of PE-PEG incorporated into liposomes
containing PS as the model reactive lipid species.
We have utilized the well-characterized binding inter-
actions of blood coagulation proteins with PS con-
taining liposomes as a model for evaluating the sur-
face properties of PEG on such liposomes. With this
system, the in£uence of PEG composition and con-
tent on PS containing lipid surfaces could be eval-
uated at several levels: (1) quantitative evaluation of
the binding of speci¢c proteins, (2) determination of
functional activity of membrane bound proteins and
protein complexes, and (3) correlation of protein
binding with liposome clearance properties after i.v.
injection. We demonstrate here that the binding bar-
rier properties of PEG in liposomes containing PS
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are substantially modi¢ed from those observed with
neutral liposomes. These results reveal opportunities
to design liposomes exhibiting selective surface chem-
istry based on inclusion of speci¢c reactive lipid com-
ponents and appropriate amounts of PEG.
2. Materials and methods
2.1. Materials
All lipids were obtained from Avanti Polar Lipids
except for 1,2-distearoyl-sn-glycero-3-phosphocholine
(DSPC) and [3H]DSPE-PEG 2000 which was ob-
tained from Northern Lipids (Vancouver, BC). The
[3H]- and [14C]cholesterylhexadecyl ether (CHE) were
from NEN/Dupont. Cholesterol, ellagic acid and Se-
pharose CL-4B were purchased from Sigma. All
blood coagulation proteins were purchased from
ICN (Aurora, OH), and the thrombin chromogenic
substrate S-2238 was purchased from Chromogenix
(Molndal, Sweden). Bio-Gel A-15m and A-5m size
exclusion gel and gel ¢ltration standards were ob-
tained from Bio-Rad (Mississauga, ON). The micro
bicinchoninic acid (micro BCA) protein assay kit was
purchased from Pierce (Rockford, IL). The Oregon
green 514 protein labeling kit was purchased from
Molecular Probes (Eugene, OR).
2.2. Preparation of large unilamellar liposomes
Lipids were prepared in chloroform solution and
subsequently dried under a stream of nitrogen gas.
The resulting lipid ¢lm was placed under high vac-
uum for a minimum of 2 h. The lipid ¢lm was hy-
drated in HEPES 20 mM/NaCl 150 mM bu¡er (pH
7.5) at 65‡C to form multilamellar vesicles. The re-
sulting preparation was frozen and thawed ¢ve times
prior to extrusion ten times through two stacked 0.1
Wm polycarbonate ¢lters (Poretics, Canada) with an
extrusion apparatus (Lipex Biomembranes, Vancou-
ver, BC) [15,16]. The extrusion temperature was kept
at 65‡C. The size of the liposomes was determined by
quasi-elastic light scattering using a Nicomp 370 sub-
micron particle sizer operating at a wavelength of
632.8 nm. Incorporation and retention of DSPE-
PEG 2000 in liposomes after preparation and subse-
quent in vivo administration were determined by size
exclusion chromatography. Brie£y, liposomes with
traces of [14C]CHE (as a general lipid marker) and
[3H]DSPE-PEG 2000 (as the PEG-lipid marker) were
applied to a 42 cmU1.3 cm Bio-Gel A-15m column
(50^100 mesh) at various concentrations, and eluted
with HEPES 20 mM/NaCl 150 mM bu¡er (pH 7.5)
at a £ow rate of 0.5 ml/min regulated by a peristaltic
pump. Aliquots from the 1 ml column fractions were
counted directly in 5.0 ml scintillation £uid.
2.3. Plasma pharmacokinetics and tissue distribution
of liposomes
Liposomes, labeled with [3H]CHE as a non-ex-
changeable, non-metabolizable lipid marker [17],
were injected via lateral tail vein with a lipid dose
of 50 mg/kg and an injection volume of 200 Wl into
approx. 22 g female CD-1 mice. At various times,
three mice from each group were terminated by
CO2 asphyxiation. Blood was collected by cardiac
puncture, and placed into EDTA-coated or hepa-
rin-coated microtainer collection tubes (Becton-Dick-
inson). After centrifuging the blood samples at 4‡C
for 15 min at 1000Ug, plasma was isolated and vis-
ually showed no hemolysis. Aliquots of the plasma
obtained were counted directly in 5.0 ml scintillation
£uid. Liver, spleen and lungs were harvested from
each group of mice to determine the biodistribution
of liposomes. Brie£y, 0.5 ml Solvable (Packard Bio-
Science) was added to whole organs (spleen and
lungs) or tissue homogenate (liver), and the mixture
was incubated at 50‡C overnight. After cooling to
room temperature, 50 Wl EDTA 200 mM, 200 Wl
hydrogen peroxide 30%, and 25 Wl HCl 10 N were
added, and the mixture was incubated for 1 h at
room temperature. The mixture was added with 5.0
ml scintillation £uid and counted 24 h later.
2.4. In vivo recovery and analysis of
liposome-associated proteins
Blood from mice injected with radiolabeled lipo-
somes was collected into heparin-coated micro-
tainers, and plasma was isolated and pooled from
four mice. The plasma (600 Wl) was applied to a
18 cmU1 cm Sepharose CL-4B column, and eluted
with HEPES 20 mM/NaCl 150 mM/CaCl2 2.5 mM
bu¡er (pH 7.5) at a £ow rate of 5.87 ml/h regulated
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by a peristaltic pump. Column fractions were ana-
lyzed for radioactivity to determine the fractions con-
taining liposomes, and the two fractions with the
highest radioactivity were pooled for the quanti¢ca-
tion of total protein associated with the recovered
liposomes. The proteins associated with the recov-
ered liposomes were extracted and delipidated ac-
cording to the procedure described by Wessel and
Flugge since lipids interfere with most protein assays
[18]. The extracted proteins were resuspended in 20 Wl
distilled water. Quanti¢cation of the proteins was
performed using the micro BCA protein assay pro-
cedure. Ten microliters of the extracted proteins was
diluted to 0.15 ml with Milli-Q water, and 0.15 ml
protein assay reagent was added. The mixture was
incubated for 2 h at 37‡C. After the mixture was
cooled to room temperature, the absorbance at 570
nm was measured with a plate reader. The extracted
proteins were quanti¢ed by a standard curve consist-
ing of known amounts of bovine serum albumin
which was linear in the range of 0^17.5 Wg/ml.
2.5. Prothrombin binding to liposomes
Bovine prothrombin was labeled with the £uores-
cent dye Oregon green 514, containing a reactive
succinimidyl ester moiety that reacts with primary
amines of the protein to form dye-protein conjugates.
The £uorescently labeled prothrombin was incubated
with various liposome compositions at lipid concen-
trations of 0.2 and 0.4 mg/ml in the presence of 2.0
mM Ca2 at 37‡C for 15 min. The mixture was then
separated using Microcon 100 ultra¢ltration devices
by centrifugation at 3000Ug for 15 min. The ¢ltrate,
containing free protein, was measured for £uores-
cence with excitation and emission wavelengths set
at 506 and 526 nm, respectively. The amount of pro-
thrombin bound to liposomes was determined using
a calibration curve constructed with known amounts
of £uorescent-labeled prothrombin and correcting
for protein recovery using liposome-free prothrom-
bin solutions.
2.6. In vitro chromogenic assay for factor Xa activity
Formation of catalytically active prothrombinase
protein complexes (factor Xa and factor Va) on lipo-
some surfaces was determined employing a chromo-
genic substrate that is cleaved by enzymatically active
thrombin [19]. Brie£y, the ‘prothrombinase complex
cocktail’ contained the components for the pro-
thrombinase conversion under the following condi-
tions: 8.0 nM (0.2 unit) factor Xa, 0.2 nM factor
Va, 6 mM CaCl2, and liposomes at various concen-
trations. These mixtures were incubated in Tris 50
mM/NaCl 120 mM bu¡er (pH 7.8) for 5 min at
37‡C. Prothrombin (1 mM) was added to the cock-
tail, and the ¢nal mixture (150 Wl) was incubated for
3 min. The conversion of prothrombin to thrombin
was stopped by the addition of EDTA (15 mM ¢nal
concentration). S-2238, which is a speci¢c chromo-
genic substrate of thrombin, was added at 0.4 mM,
and the rate of chromogen formation was monitored
at 405 nm with a plate reader equipped with kinetic
analysis software (Dynex Technologies, Chantilly,
VA). A calibration curve was obtained under the
same conditions with known amounts of thrombin,
and the amount of thrombin formed in the assay was
determined from the calibration curve.
2.7. In vitro clotting time assay
This assay was based on the activated partial
thromboplastin time. An ellagic acid solution was
used freshly prepared and diluted in 20 mM
HEPES/150 mM NaCl. Human citrated plasma (50
Wl) was preincubated with 1035 M ellagic acid (50 Wl)
and liposomes (50 Wl) for 2 min at 37‡C. Calcium
was then added to initiate the clotting reaction.
The time at which the mixture changed from a liquid
to a viscous gel was recorded, and was noted as the
time for the clotting reaction to be completed.
3. Results
3.1. E¡ect of PEG-lipids on the plasma
pharmacokinetics and the tissue distributions of
PS containing liposomes
Liposomes containing PS are rapidly eliminated
from the circulation, a phenomenon believed to be
due to extensive binding of plasma proteins and up-
take by the MPS [14]. This can be seen in Fig. 1,
which presents the plasma pharmacokinetics of 10
mol% PS liposomes containing various amounts of
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DSPE-PEG 750 (Fig. 1A) or DSPE-PEG 2000 (Fig.
1B). Whereas conventional neutral DSPC/cholesterol
(Chol) liposomes exhibited a monophasic plasma
elimination curve with s 10% of the injected dose
remaining at 8 h post injection, inclusion of 10
mol% PS in DSPC/Chol liposomes changed the plas-
ma elimination curve to a biphasic shape with 6 1%
of the liposomes in plasma within 1 h. The circula-
tion longevity of DSPC/Chol liposomes was dramat-
ically decreased with the inclusion of 10 mol% PS, as
re£ected by the concentration of liposomes remain-
ing in the circulation which was reduced from 0.23
mg/ml to 0.0019 mg/ml 4 h post injection. The mean
AUC0ÿ24h for DSPC/Chol liposomes was also re-
duced from 4.02 to 0.65 mg ml31 h with the inclusion
of 10 mol% PS.
The incorporation of DSPE-PEG 750 or DSPE-
PEG 2000 generally provided protection of the PS
liposomes from plasma clearance, re£ected by the
trend that increasing PEG-lipid content in the PS
liposomes increased the circulation longevity of the
PS liposomes (Fig. 1A,B). However, the protecting
e¡ect of DSPE-PEG against liposome clearance was
signi¢cantly increased for PEG 2000 compared to
PEG 750. Incorporation of DSPE-PEG 750 into
the liposomes at 20 mol%, which is the maximum
concentration without inducing micelle formation
[20], increased the circulation lifetime of PS lipo-
somes as re£ected by an increase in the 4 h plasma
lipid concentration to 0.035 mg/ml. This was signi¢-
cantly lower than the 4 h plasma lipid concentration
of 0.23 mg/ml observed for DSPC/Chol liposomes.
Similar results were observed when 5 mol% DSPE-
PEG 2000 was incorporated into PS containing lipo-
somes (Fig. 1B). In contrast, incorporation of 10
mol% of DSPE-PEG 2000 into PS containing lipo-
somes resulted in plasma elimination curves that
were comparable to those obtained for DSPC/Chol
liposomes devoid of PS (Fig. 1B). Furthermore, in-
creasing the DSPE-PEG 2000 content to 15 mol%,
which is the maximum incorporation level of DSPE-
PEG 2000 for bilayer stability, resulted in plasma
liposome elimination curves that approached those
observed for PS-free sterically stabilized liposomes
(5 mol% DSPE-PEG 2000 in DSPC/Chol liposomes).
Inclusion of 15 mol% DSPE-PEG 2000 into 10 mol%
PS liposomes increased the mean AUC0ÿ24h by 12-
fold from 0.65 mg ml31 h to 7.97 mg ml31 h.
The trends observed in liposome plasma elimina-
tion time correlated closely with liposomal lipid lev-
els observed in the major MPS organs, the liver and
spleen. Speci¢cally, the plasma liposome levels were
inversely proportional to the liver and spleen lipo-
some recovery 4 h after i.v. injection. The inclusion
Fig. 1. The e¡ect of incorporating (A) DSPE-PEG 750 and (B)
DSPE-PEG 2000 on the plasma elimination of PS liposomes.
Three mice were used for each data point, and the error bars
represent the standard errors. The plasma elimination curves
for the following liposomes were determined and plotted in
(A): DSPC/Chol 55:45 (F), DOPS/DSPC/Chol 10:45:45 (b),
DSPE-PEG 750 incorporated at 10 mol% (R) and 20 mol%
(S) in DOPS 10%/DSPC/Chol 45%. The plasma elimination
curves for the following liposomes were determined and plotted
in (B): DSPC/Chol 55:45 (F), DOPS/DSPC/Chol 10:45:45 (b),
DSPE-PEG 2000 incorporated at 5 mol% (R), 10 mol% (S)
and 15 mol% (8) in DOPS 10%/DSPC/Chol 45%, and DSPE-
PEG 2000/DSPC/Chol 5:50:45 (E).
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of 10 mol% PS in DSPC/Chol liposomes increased
the amount of lipid accumulated in liver from 0.29 to
0.63 mg/g tissue and in spleen from 1.27 to 2.47 mg/g
tissue. Incorporating DSPE-PEG 750 or DSPE-PEG
2000 into 10 mol% PS liposomes decreased the
amount of lipid accumulated in liver and spleen.
For example, when 15 mol% DSPE-PEG 2000 was
incorporated into the PS liposomes, a ¢ve-fold reduc-
tion in the amount of lipid accumulated in liver and
spleen was observed (data not shown).
3.2. Evaluation of liposome-protein interactions after
in vivo injection
The extended circulation time of sterically stabi-
lized liposomes has been attributed to the ability of
PEG-lipids to reduce protein binding and cell inter-
actions [3,4]. In this study, the amount of protein
associated with liposomes recovered from mice 30
min post injection was determined with the micro
BCA protein assay (Table 1). Liposomes with 10
mol% PS in the absence of PEG-lipids had the high-
est amount of associated protein per mole of recov-
ered liposomal lipid (20.0 g protein/mol lipid). In
contrast, the amount of protein associated with the
sterically stabilized 5 mol% DSPE-PEG 2000/DSPC/
Chol liposomes was 5.86 g protein/mol lipid. The
incorporation of 10 mol% DSPE-PEG 2000 into
the 10 mol% PS liposomes provided moderate reduc-
tion in the amount of liposome-associated protein
(7.49 g protein/mol lipid). When 15 mol% DSPE-
PEG 2000 was incorporated into the 10 mol% PS
liposomes, the amount of associated protein was re-
duced to 4.03 g protein/mol lipid, which re£ected a
¢ve-fold reduction when compared to values of non-
pegylated PS containing liposomes (Table 1). Thus,
as the mole percentage of DSPE-PEG 2000 was in-
creased in the PS liposomes, the circulation time of
PS liposomes was extended with reduced plasma pro-
tein binding and decreased accumulation in the MPS
organs.
3.3. Incorporation of DSPE-PEG 2000 into
PS liposomes
From the results of the in vivo studies, DSPE-PEG
2000 needed to be incorporated at 15 mol% in PS
liposomes to reduce plasma protein interactions. At
such high levels, there are potential concerns regard-
ing the incorporation e⁄ciency of the PEG-lipids. In
particular, formation of micelles has been demon-
strated when the level of DSPE-PEG 2000 was
more than 15 mol% in liposomes [20^22], which is
close to the level used here for extending the circu-
lation longevity of PS liposomes. Therefore, the in-
corporation of 15 mol% DSPE-PEG 2000 into 10
mol% PS liposomes was examined with size exclusion
chromatography to separate liposomes from DSPE-
PEG 2000 micelles. The ability of the Bio-Gel A-15m
gel ¢ltration column to resolve liposomes from
DSPE-PEG 2000 micelles was ¢rst con¢rmed by ap-
plying liposomes and DSPE-PEG 2000 micelles to
the column immediately after mixing. As shown in
the inset of Fig. 2, liposomes eluted at the exclusion
volume of the column while DSPE-PEG 2000 mi-
celles eluted near the inclusion volume. Further sep-
aration on a Bio-Gel A-5m gel ¢ltration column and
comparison with molecular weight standards indi-
cated that the micelles exhibited an average size of
approx. 670 000 Da (data not shown). This demon-
strated that DSPE-PEG 2000 micelles could be sep-
arated from liposomes in mixed solutions, and this
Table 1
PB valuesa for liposomes recovered from murine plasma 30 min post injection of liposomes
Liposomes In vivo PB value (g protein/mol lipid)
DSPE-PEG 2000/DSPC/Chol 5:50:45 5.86
1,2-Dioleoyl-sn-glycero-3-[phospho-L-serine] (DOPS)/DSPC/Chol 10:45:45 20.0
DSPE-PEG 2000/DOPS/DSPC/Chol 10:10:40:45 7.49
DSPE-PEG 2000/DOPS/DSPC/Chol 15:10:30:45 4.03
aPB value was de¢ned as the amount of protein associated with each mole of lipid recovered from murine plasma 30 min post injec-
tion in a single determination. Due to low recovery of lipids from animals, plasma from four mice was pooled, and chromatographed
on a Sepharose CL-4B column under similar conditions. Column fractions containing the liposomes were pooled, and the amount of
protein was determined by the micro BCA assay as described in Section 2.
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could be used to determine the retention of DSPE-
PEG 2000 in liposomes when prepared at high incor-
poration levels.
Fig. 2A shows that no micelle peak was observed
in the elution pro¢le of the stock preparation (54
mM) of 10 mol% PS liposomes containing 15
mol% DSPE-PEG 2000. Identical elution pro¢les
were obtained when the stock liposomes were diluted
to the concentrations used in in vitro (0.2 mM) and
in vivo (6.2 mM) experiments (data not shown).
Based on the ratio of the radiolabeled DSPE-PEG
2000 and liposome marker ([14C]CHE), the amount
of DSPE-PEG 2000 present in PS liposome contain-
ing fractions re£ected a DSPE-PEG 2000 composi-
tion of 14 mol% for all of the liposome concentra-
tions. For comparison, DSPC/Chol liposomes
containing 15 mol% DSPE-PEG 2000 were assayed
with the same technique, and a similar elution pro¢le
was observed, with over 14 mol% DSPE-PEG 2000
being incorporated into the liposomes (Fig. 2B).
These data indicate that PEG-lipid content up to
15 mol% can be incorporated into liposomes, and
Fig. 2. Size exclusion chromatography with Bio-Gel A-15m column of (A) 10 mol% PS liposomes and (B) DSPC/Chol liposomes,
each containing 15 mol% DSPE-PEG 2000, at stock concentrations (54 mM). Both types of liposomes were labeled with traces of
[14C]CHE (b) as a lipid marker and [3H]DSPE-PEG 2000 (F). The calibration of the Bio-Gel A-15m column with DOPS/DSPC/Chol
10:45:45 liposomes (b) and DSPE-PEG 2000 micelles (F) is shown in the inset.
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that PEG-lipid micelles could not be detected during
the preparation or the dilution of liposomes contain-
ing up to 15 mol% DSPE-PEG 2000.
The retention of DSPE-PEG 2000 in liposomes
after intravenous administration was also investi-
gated, since the loss of PEG-lipids from liposomes
could compromise the shielding of PS liposomes
from plasma components. Ten mol% PS liposomes
and PS-free DSPC/Chol liposomes, both containing
15 mol% DSPE-PEG 2000, were injected into mice to
determine the amount of DSPE-PEG 2000 retained
by the liposomes in plasma at various times post
injection (Table 2). Approx. 13 mol% DSPE-PEG
2000 remained associated with the 10 mol% PS lipo-
somes and DSPC/Chol liposomes in the circulation
over 24 h. The incorporation and the retention of 15
mol% DSPE-PEG 2000 were not speci¢c to PS lipo-
somes, since similar gel ¢ltration column pro¢les (see
Fig. 2B) and in vivo DSPE-PEG 2000 retention were
observed with 15% DSPE-PEG 2000/DSPC/Chol
liposomes (see Table 2).
3.4. E¡ects of DSPE-PEG 2000 on prothrombin to
PS liposomes
The results from our in vivo studies have shown
that an elevated PEG-lipid content (15 mol%) was
e¡ective in reducing plasma protein binding of PS
liposomes, and that the protection of PS liposomes
was dependent on the molecular weight of the PEG
polymer, with higher molecular weight (PEG 2000)
being more e¡ective. In light of these results, we
postulated that Mr 2000 PEG-lipids, incorporated
at an elevated level (15 mol%), may be e¡ective in
protecting the PS liposome surface from the high
a⁄nity, PS-mediated binding of plasma proteins.
We investigated this concept by utilizing the well-
characterized interactions of blood coagulation pro-
teins with PS membranes as a model to evaluate the
‘steric stabilizing’ e¡ect of PEG-lipids on such reac-
tive membranes.
Calcium-dependent prothrombin binding to 10
mol% PS liposomes was determined using £uores-
cently labeled protein and separating free and lipo-
some bound pools under equilibrium conditions with
ultra¢ltration devices [23]. Fluorescent derivatization
did not signi¢cantly alter the binding properties of
prothrombin to PS containing liposomes as free vs.
bound protein fractions were similar to those for
prothrombin binding to PS containing liposomes re-
ported previously using light scattering techniques
[23]. Negligible prothrombin association with lipo-
somes was observed in the absence of PS under con-
ditions where between 25% and 40% of the protein in
solution was bound to 10 mol% PS liposomes with
initial prothrombin to lipid weight ratios of 0.25:1
and 0.1:1 respectively. Incorporation of DSPE-PEG
2000 at 5 mol% in DSPC/Chol (50:45 molar ratio)
liposomes resulted in 28% and 37% inhibition of pro-
thrombin binding at protein/lipid weight ratios of
0.25:1 and 0.1:1, respectively (Fig. 3). Increasing
the amount of DSPE-PEG 2000 to 10 mol% and
15 mol% signi¢cantly enhanced the inhibition of pro-
thrombin binding to the 10% PS liposomes where an
85% decrease in protein binding was observed using
15% DSPE-PEG 2000 at a protein to lipid weight
ratio of 0.1:1 and a 75% protein binding decrease
was obtained at the 0.25:1 protein to lipid ratio.
Table 2
Mole percentage of DSPE-PEG 2000 remaining in liposomes recovered from murine plasma at various hours post injection of lipo-
somes
Time (h) Mole% of DSPE-PEG 2000 remaining in liposomes
( þ S.D.)a
DSPE-PEG 2000/DOPS/DSPC/Chol 15:10:30:45b 1 14.3 þ 0.1
4 13.9 þ 0.2
24 13.4 þ 0.1
DSPE-PEG 2000/DSPC/Chol 15:40:45b 1 14.5 þ 0.4
4 14.1 þ 0.1
24 12.6 þ 0.2
aData represent the average þ S.D. of three mice. The injected lipid dose was 50 mg/kg.
bThe liposomes were dual-labeled with [14C]CHE (as a general lipid marker) and [3H]DSPE-PEG 2000 and prepared as described in
Section 2.
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3.5. E¡ects of PEG-lipids on the functional activity of
membrane bound blood coagulation proteins
The results above demonstrate that the degree of
inhibition of prothrombin binding to PS liposomes is
related to increasing PEG-lipid content. We then ex-
tended these observations to examine e¡ects of PEG-
lipids on the functional activity of membrane bound
blood coagulation proteins. We ¢rst investigated the
e¡ect of PEG-lipids on the catalytic activity of the
prothrombinase complex, which consists of factors
Xa and Va assembled on negatively charged mem-
brane surfaces and is responsible for the proteolytic
activation of prothrombin to thrombin. The rate of
thrombin formation by the prothrombinase complex
in the presence of liposomes was monitored using a
chromogenic substrate that is activated by thrombin.
In DSPC/Chol liposomes (0 mol% PS), the rate of
thrombin formation was negligible, and no substrate
activation was observed in the absence of liposomes.
Incorporating 10 mol% PS into DSPC/Chol lipo-
somes resulted in a rate of thrombin formation of
1.94 mol thrombin/min/mol factor Xa (Table 3).
The e¡ectiveness of DSPE-PEG 750 and DSPE-
PEG 2000 in inhibiting the assembly and the cata-
lytic activity of the prothrombinase complex on the
PS membrane surface were evaluated. With 10 mol%
DSPE-PEG 750 or 5 mol% DSPE-PEG 2000 in
10 mol% PS liposomes, the rates of thrombin forma-
tion were 2.48 and 1.96 mol thrombin/min/mol factor
Xa respectively, which were similar to those for the
non-pegylated PS liposomes. Only by elevating the
PEG-lipid content to 20 mol% for DSPE-PEG 750
or 10^15 mol% for DSPE-PEG 2000 could the rate
of thrombin formation be substantially reduced to
6 0.465 mol thrombin/min/mol factor Xa (minimum
detectable rate).
In addition to the prothrombinase complex, the PS
membrane surface is required for the proteolytic ac-
tivation of several additional blood coagulation pro-
teins and propagation of the blood coagulation cas-
cade [11,24]. Also, full clot formation requires the
release of thrombin from the prothrombinase com-
plex which can then enzymatically convert ¢brinogen
to ¢brin. We therefore determined the impact of
PEG-lipids on the comprehensive procoagulant ac-
tivity of PS liposomes using an assay which mea-
sured the activated partial thromboplastin time
where exogenously added liposomes provided the
catalytic membrane surface. First, the clotting times
Table 3
Rate of thrombin formation in the presence of various lipo-
somes assayed by the in vitro chromogenic assay
Liposomes Mol thrombin/min/mol
factor Xa þ S.D.a
DSPC/Chol 55:45 N.D.b
DOPS/DSPC/Chol 10:45:45 1.94 þ 0.24
DSPE-PEG 2000/DOPS/DSPC/Chol
5:10:40:45
1.96 þ 0.34
DSPE-PEG 2000/DOPS/DSPC/Chol
10:10:35:45
N.D.
DSPE-PEG 2000/DOPS/DSPC/Chol
15:10:30:45
N.D.
DSPE-PEG 750/DOPS/DSPC/Chol
10:10:35:45
2.48 þ 0.18
DSPE-PEG 750/DOPS/DSPC/Chol
20:10:25:45
N.D.
aData represent the averages þ S.D. of three experiments. Lipo-
some concentrations used were 75 WM.
bN.D. represents non-detectable levels which were characterized
by the assay system to be below 0.46 mol thrombin/min/mol
factor Xa.
Fig. 3. The e¡ect of DSPE-PEG 2000 on the binding of pro-
thrombin to 10 mol% PS liposomes at two di¡erent prothrom-
bin to liposome ratios: 0.1 w/w (b) and 0.25 w/w (F). The %
inhibition was calculated as follows: % inhibition = (FPEG3FPS)/
(Fcontrol3FPS)U100, where F represents the £uorescence of the
unbound protein in the ¢ltrate after centrifugation with the Mi-
crocon 100 ultra¢ltration device and the subscripts represent
the di¡erent types of liposomes tested as described in Section 2.
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of liposomes with various mol% PS were compared
in order to establish baseline procoagulant activity of
the liposomes as well as conditions for comparative
experiments (Fig. 4). In the absence of phospholip-
ids, the time to form the ¢brin clot was approx. 350 s
(data not shown), while the addition of neutral
DSPC/Chol liposomes at 0.02 mM and 0.5 mM de-
creased the clotting time to 310 s and 255 s, respec-
tively. The inclusion of 10^20 mol% PS in DSPC/
Chol liposomes further decreased the clotting times
to approx. 120 s when the liposome concentration
was below 0.1 mM. This reduction in clotting times
re£ected that the presence of a negatively charged
phospholipid membrane surface enhanced the blood
coagulation reactions. The clotting time of 20 mol%
PS liposomes increased to 152 s as the liposome con-
centration was increased to 0.36 mM; however, the
clotting times of 10 mol% PS liposomes were main-
tained at approx. 120 s throughout the range of lipo-
some concentrations used in the assay. The increase
in clotting time observed with 20 mol% PS liposomes
as the liposome concentration increased is consistent
with an excess of the catalytic surface. This excess
catalytic surface results in surface-dilution e¡ects of
the blood coagulation proteins leading to decreased
thrombogenic activity [11]. These results demon-
strated that both 10 and 20 mol% PS liposomes
had signi¢cant procoagulant activity, and were uti-
lized to evaluate the e¡ectiveness of DSPE-PEG 750
Fig. 5. The use of (A) DSPE-PEG 750 and (B) DSPE-PEG
2000 to inhibit the clotting activity of PS liposomes. The % in-
hibition was calculated as follows: % inhibition = (tPEG3tPS)/
(tblank3tPS)U100, where t represents the clotting time of each
type of liposome as determined by the in vitro clotting time as-
say. Liposomes with 10 mol% (b) and 20 mol% (a) of DOPS
in DSPC/Chol were compared. The liposome concentrations
used in A and B were 0.4 mM and 0.2 mM respectively. Data
points were determined in triplicate, and the error bars repre-
sent standard deviations.
Fig. 4. Clotting activity of DSPC/Chol liposomes with di¡erent
mol% DOPS as determined by the in vitro clotting time assay.
The clotting times were measured for 0 mol% (F), 5 mol% (b),
10 mol% (R) and 20 mol% (8) of DOPS incorporated with
DSPC/Chol as the bulk lipids. Data points were determined in
triplicate, and the error bars represent standard deviations.
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and DSPE-PEG 2000 in impeding the propagation of
the blood coagulation cascade.
The percent inhibition of clotting activity of 10
and 20 mol% PS liposomes by the PEG-lipids is pre-
sented in Fig. 5A,B. When incorporated at 9 10
mol%, DSPE-PEG 750 inhibited approx. 15% of
the clotting activity for 10 and 20 mol% PS lipo-
somes. The inhibitory e¡ect of DSPE-PEG 750 was
sigmoidal, as re£ected by the increase in the percent
inhibition of the clotting activity for 10 and 20 mol%
PS liposomes. When the level of DSPE-PEG 750 in
PS liposomes was increased to 20 mol%, the inhibi-
tion of procoagulant activity was increased to 85%
and 65% for 10 and 20 mol% PS liposomes, respec-
tively (Fig. 5). A similar trend was observed with
DSPE-PEG 2000 where low levels of the PEG-lipid
in the PS liposomes provided only modest inhibition
to the clotting activity. Speci¢cally, when DSPE-
PEG 2000 was incorporated at 5 mol%, 40% and
8% of the clotting activity was inhibited for 10 and
20 mol% PS liposomes, respectively. This inhibitory
e¡ect was increased to approx. 80% when the level of
DSPE-PEG 2000 was increased to 15 mol% in the
two PS liposomes. These results agreed well with
those obtained for prothrombin binding and pro-
thrombinase complex activity determined with the
chromogenic assay.
4. Discussion
Surface modi¢cation of liposomes with the hydro-
philic polymer PEG has provided a major advance in
drug delivery applications due to the ability of this
polymer to reduce protein binding and plasma elim-
ination of liposomes. The mechanism by which the
PEG polymer protects the liposome surface has been
attributed to (1) the hydrophilicity of the polymer
that e¡ectively provides a ‘water shell’ to the lipo-
some surface, and (2) the £exibility of the polymer
that gives a large number of conformations, resulting
in a ‘statistical cloud’ which sterically protects the
liposome surface [5,25]. Most of the studies on
PEG-lipids have focused on the protection of neutral
liposome surfaces from plasma protein binding and
subsequent MPS uptake. In this context, several
studies have demonstrated that 5^7 mol% DSPE-
PEG 2000 is optimal for protection of such lipo-
somes [5,10]. However, the use of PEG-lipids to pro-
tect a biologically active membrane surface has not
been well documented. In this study, liposomes con-
taining PS were used as the model for a biologically
active membrane, and the ability of the PEG-lipids
to protect this liposome surface was tested under
both in vitro and in vivo conditions.
One of the ¢rst questions that arose in this study
was the feasibility of incorporating PEG-lipids at
elevated levels into liposomes. This is due to reports
that DSPE-PEG 2000 incorporation beyond 7^8
mol% into phospholipid liposomes can lead to alter-
nate lipid phases primarily arising from DSPE-PEG
micelle formation [5,10]. However, our results dem-
onstrated DSPE-PEG 2000 can be readily incorpo-
rated into DSPC/Chol-based liposomes up to 15
mol% without the generation of micelles. Further,
the in vivo retention and stability of the PEG-lipids
in liposomes exposed to the biological milieu argue
against micelle formation. These results are in good
agreement with another study which demonstrated
that DSPE is a more stable anchor for PEG 2000
than 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphatidyl-
ethanolamine (POPE) with respect to PE-PEG reten-
tion in liposomes [26].
In contrast to neutral liposomes such as DSPC/
Chol where 5^7 mol% DSPE-PEG 2000 provides
protection for protein binding, biologically active
liposomes containing PS with these levels of PEG-
lipids are still capable of interacting with relatively
large proteins. Only when the PEG-lipids were
present at higher mole percentages was prothrombin
binding signi¢cantly inhibited. This observation is
somewhat surprising since studies by Needham et
al. [7] have demonstrated that the kon for similarly
sized proteins or lysolipid micelles (compared to 1800
Aî 2 per molecule surface coverage for prothrombin,
see [27]) interacting with a membrane surface is de-
creased approx. 100-fold when DSPE-PEG 750 or
DSPE-PEG 2000 are incorporated into phosphati-
dylcholine (PC) bilayers at 12% and 6%, respectively.
The fact that 20% DSPE-PEG 750 or 15% DSPE-
PEG 2000 are required to signi¢cantly inhibit pro-
thrombinase protein interactions with PS containing
liposomes indicates that these protein molecules can
penetrate through the PEG layer at lower polymer
levels (e.g. 5 mol% DSPE-PEG 2000). Similar PEG
content dependences observed for inhibition of pro-
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thrombin binding, chromogenic prothrombinase ac-
tivity and complete clotting activity indicate that
even the large ternary protein prothrombinase com-
plex (in excess of 7000 Aî 2 surface coverage) can as-
sociate on PS membranes containing 6 10% PEG
2000.
Three key features may account for the altered
steric stabilization e¡ects of PEG-DSPE observed
for the protein membrane interactions studied here.
First, the electrostatic attraction that exists between
negatively charged PS molecules and binding ligands
on the coagulation proteins could provide some of
the energy necessary for the additional work required
to move proteins through the PEG layer. This could
decrease the e¡ect of PEG on kon for PS coagulation
protein binding compared to non-speci¢c protein-
neutral membrane interactions. Second, the high
binding a⁄nities of coagulation proteins for PS con-
taining liposomes (Kd values ranging from 7U1038
M to 2.5U10310 M, see [28,29]) arise primarily from
signi¢cant decreases in koff where collisional binding
e⁄ciencies s 30% have been documented for pro-
teins of the prothrombinase complex [28]. This is in
contrast to the very ine⁄cient contact phase of pro-
tein adsorption to neutral membrane surfaces [28,29].
Consequently, the ability of prothrombin and other
blood coagulation proteins to bind to PS containing
liposomes in the presence of 5% PEG 2000 may be
kinetically driven due to the very slow release of
protein once initial contact with the membrane has
been made through transient openings in the steric
PEG barrier that have been shown to occur at PEG
2000 concentrations as high as 10 mol% [30].
The third membrane binding feature for pro-
thrombin, factor X and factor V, that may impact
on the steric stabilization properties of PEG-lipids is
their multivalent interaction with PS at the mem-
brane surface. Eight PS molecules are required to
bind one prothrombin molecule and the total PS
requirement for binding all three proteins of the pro-
thrombinase complex is between 40 and 50 molecules
[31]. Assuming an average area per PS molecule of
approx. 60 Aî 2, 27% of the area covered by one pro-
thrombin molecule is occupied by PS, re£ecting a
2.7-fold enrichment of PS in this region. Similarly,
the approx. 7000 Aî 2 covered by the complete pro-
thrombinase complex (prothrombin, factor X and
factor V) would be predicted to have a lipid compo-
sition consisting of between 40 and 50 mol% PS.
Previous studies have demonstrated that these pro-
teins are capable of inducing lateral separation of PS
in PS/PC liposomes [23]. Such membrane microdo-
mains enriched in PS would be largely devoid of
DSPE-PEG, thereby providing potential nucleation
sites for protein binding where the steric barrier as-
sociated with PEG-lipids would be absent.
We propose that compression of the packing area
per PEG molecule at the liposome surface is neces-
sary as DSPE-PEG 2000 is being excluded from the
protein binding sites under this PS-enriched protein
binding microdomain model. This prediction can be
made due to the fact that prothrombinase protein
binding is mediated through the PS head group at
the lipid/water interface and does not require protein
insertion into the hydrophobic portion of the bilayer
[32]. Previous studies have documented that the
packing area per PEG molecule was 960 Aî 2 and
480 Aî 2 for levels of 5 and 10 mol% incorporation
respectively, based on a PEG volume of 31 500 Aî 3
[33]. We propose that DSPE-PEG 2000 can be fur-
ther compressed to a PEG packing area of 330 Aî 2
per molecule and an extension of 100 Aî from surface
at 15 mol% incorporation (see Fig. 6). For PS lipo-
somes containing 5 and 10 mol% DSPE-PEG 2000,
this means that 67% and 33% of liposome surface
can be made available for protein binding if the
PEG molecule is compressed to 330 Aî 2. The level
of prothrombin binding to PS liposomes with 5 and
10 mol% DSPE-PEG 2000 was approx. 70% and
30%, respectively, of that obtained in the absence
of PEG which is consistent with the PEG compres-
sion model described above. The combined e¡ects of
densely packed PEG and extension of the polymer
barrier from the membrane surface under these con-
ditions appear to provide steric inhibition of even
high a⁄nity protein-membrane interactions. It re-
mains to be determined whether much smaller mol-
ecules are able to penetrate to the liposome surface
under these densely packed conditions.
It is of particular interest that the relationship of
DSPE-PEG 2000 incorporation with in vivo circula-
tion lifetime and protein binding closely matched the
results of speci¢c in vitro assays for inhibition of
coagulation protein-PS binding. This suggests that
the altered steric stabilization e¡ects of PEG in mem-
branes containing signi¢cant concentrations of reac-
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tive lipid species may have signi¢cant implications
beyond the interactions of blood coagulation pro-
teins. The pharmacokinetic studies here are the ¢rst
to document e¡ective protection of PS liposomes
from plasma protein binding and removal from cir-
culation by MPS in the absence of phagocytic poi-
sons. Speci¢cally, 10% PS liposomes containing 15%
DSPE-PEG 2000 displayed plasma elimination
curves as well as liver and spleen uptake that were
comparable to those for traditional ‘stealth’ DSPE-
PEG 2000 5%/DSPC/Chol liposomes. This suggests
that liposomes containing surface grafted PEG and
reactive lipids may be appropriately designed to se-
lect for speci¢c interactions with plasma components
based on molecular size and membrane binding af-
¢nities. Such applications may provide additional
£exibility in developing therapeutic liposomes with
improved targeting and disease site speci¢c activation
properties.
Acknowledgements
We are grateful to Dana Masin, Natashia McIn-
tosh and Rebecca Ng for their technical assistance in
the animal studies. This research project is supported
by a research grant from the Medical Research
Council of Canada. G.N.C.C. is supported by a
graduate fellowship from the University of British
Columbia.
References
[1] D. Papahadjopoulos, T.M. Allen, A. Gabizon, K. Mayhew,
S.K. Huang, L.D. Lee, M.C. Woodle, D.D. Lasic, C. Re-
demann, F.J. Martin, Proc. Natl. Acad. Sci. USA 88 (1991)
11460^11464.
[2] H.M. Patel, Crit. Rev. Ther. Drug Carrier Syst. 9 (1992) 39^
90.
[3] G. Blume, G. Cevc, Biochim. Biophys. Acta 1146 (1993)
157^168.
[4] D.D. Lasic, F.J. Martin, A. Gabizon, S.K. Huang, D. Pa-
pahadjopoulos, Biochim. Biophys. Acta 1070 (1991) 187^
192.
[5] O. Tirosh, Y. Barenholz, J. Katzhendler, A. Priev, Biophys.
J. 74 (1998) 1371^1379.
[6] V.P. Torchilin, V.G. Omelyanenko, M.I. Papisov, A.A. Bog-
danov, V.S. Trubetskoy, J.N. Herron, C.A. Gentry, Bio-
chim. Biophys. Acta 1195 (1994) 11^20.
[7] D. Needham, N. Stoicheva, D.V. Zhelev, Biophys. J. 73
(1997) 2615^2629.
[8] H. Du, P. Chandaroy, S.W. Hui, Biochim. Biophys. Acta
1326 (1997) 236^248.
[9] A. Klibanov, K. Maruyama, A.M. Beckerleg, V.P. Torchilin,
L. Huang, Biochim. Biophys. Acta 1062 (1991) 142^148.
[10] T.M. Allen, C. Hansen, F. Martin, C. Redemann, A. Yau-
Young, Biochim. Biophys. Acta 1066 (1991) 29^36.
[11] R.F.A. Zwaal, Biochim. Biophys. Acta 515 (1978) 163^
205.
[12] J. Szebeni, Crit. Rev. Ther. Drug Carrier Syst. 15 (1998) 57^
88.
[13] S.J. Martin, C.P.M. Reutelingsperger, A.J. McGahon, J.A.
Rader, R.C.C.A. VanSchie, D.M. Laface, D.R. Green,
J. Exp. Med. 182 (1995) 1545^1556.
[14] T.M. Allen, P. Williamson, R.A. Schlegel, Proc. Natl. Acad.
Sci. USA 85 (1988) 8067^8071.
[15] L.D. Mayer, M.J. Hope, P.R. Cullis, A.S. Jano¡, Biochim.
Biophys. Acta 817 (1985) 193^196.
[16] L.D. Mayer, M.J. Hope, P.R. Cullis, Biochim. Biophys.
Acta 858 (1986) 161^168.
[17] Y. Stein, G. Halperin, O. Stein, FEBS Lett. 111 (1980) 104^
106.
[18] D. Wessel, U.I. Flugge, Anal. Biochem. 138 (1984) 141^143.
[19] J. Connor, C. Bucana, I.J. Fidler, A.J. Schroit, Proc. Natl.
Acad. Sci. USA 86 (1989) 3184^3188.
[20] A.K. Kenworthy, S.A. Simon, T.J. McIntosh, Biophys. J. 68
(1995) 1903^1920.
[21] K. Hristova, D. Needham, Macromolecules 28 (1995) 991^
1002.
[22] K. Hristova, A. Kenworthy, T.J. McIntosh, Macromolecules
28 (1995) 7693^7699.
Fig. 6. An illustration of the PS-enriched protein binding mi-
crodomain model. DSPE-PEG 2000 is laterally excluded from
the protein binding site (indicated by black arrows) when pro-
teins bind to the PS membrane surface mediated by the PS
head group (black circles). Compression of the packing area
per PEG molecule at the liposome surface from 1000 Aî 2 (at
5 mol% DSPE-PEG 2000) to 330 Aî 2 is proposed to be neces-
sary for accommodating the bound proteins.
BBAMEM 77997 26-1-01
G.N.C. Chiu et al. / Biochimica et Biophysica Acta 1510 (2001) 56^6968
[23] L.D. Mayer, G.L. Nelsestuen, Biochemistry 20 (1981) 2457^
2463.
[24] M. Kalafatis, J.O. Egan, C. van ’t Veer, K.M. Cawthern,
K.G. Mann, Crit. Rev. Eukaryotic Gene Expr. 7 (1997) 241^
280.
[25] V.P. Torchilin, M.I. Papisov, J. Lipid Res. 4 (1994) 725^739.
[26] M.J. Parr, S.M. Ansell, L.S. Choi, P.R. Cullis, Biochim.
Biophys. Acta 1195 (1994) 21^30.
[27] T.K. Lim, V.A. Bloom¢eld, G.L. Nelsestuen, Biochemistry
16 (1977) 4177^4181.
[28] M.L. Pusey, L.D. Mayer, G.J. Wei, V.A. Bloom¢eld, G.L.
Nelsestuen, Biochemistry 21 (1982) 5262^5269.
[29] L.D. Mayer, G.L. Nelsestuen, H.L. Brockman, Biochemistry
22 (1983) 316^321.
[30] S. Rex, M.J. Zuckermann, M. La£eur, J.R. Silvius, Biophys.
J. 75 (1998) 2900^2914.
[31] G.L. Nelsestuen, M. Broderius, Biochemistry 16 (1977)
4172^4177.
[32] L.D. Mayer, M.L. Pusey, M.A. Griep, G.L. Nelsestuen, Bio-
chemistry 22 (1983) 6226^6232.
[33] T.L. Kuhl, D.E. Leckband, D.D. Lasic, J.N. Israelachvili,
Biophys. J. 66 (1994) 1479^1488.
BBAMEM 77997 26-1-01
G.N.C. Chiu et al. / Biochimica et Biophysica Acta 1510 (2001) 56^69 69
